English Journal

Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study.

Kawabata M1, Kaneishi K.
The American journal of hospice & palliative care.Am J Hosp Palliat Care.2013 May;30(3):305-11. doi: 10.1177/1049909112448924. Epub 2012 Jun 5.
Pain and dyspnea are the most prevalent and distressing symptoms in patients with terminally ill cancer. Evidences have accumulated for the effects of morphine on dyspnea, whereas little is known about the effects of oxycodone on dyspnea. We investigated the effectiveness of oxycodone for dyspnea in
PMID 22669937

[Retrospective study on intravenous compound injection of cancer pain patients with oxycodone and hydrocotarnine preparation in comparison with subcutaneous administration].

Sano T1, Akagi T, Yokote N, Shuto C, Kudo N, Miura K, Murakami S, Saito O, Yamamoto H, Matoba M.
Gan to kagaku ryoho. Cancer & chemotherapy.Gan To Kagaku Ryoho.2012 May;39(5):769-75.
In Japan, although oral oxycodone is widely used for cancer pain treatment, there is no injection preparation of oxycodone used as a single ingredient. Only the compound injection of oxycodone and hydrocotarnine has received approval. Subcutaneous administration of the drug is approved, but there ar
PMID 22584329

[Solutions for the clinical problems of analgesics for cancer pain treatment in Japan].

Kokubun H1, Matoba M, Yamada Y, Yago K.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.Yakugaku Zasshi.2011 Jan;131(1):113-27.
The pain experienced by cancer patients can be managed in 70-90% of cases by the World Health Organisation protocol for cancer pain. However, cancer pain treatment in Japan is not sufficiently effective. To use medicine safely and effectively, various problems must be solved. Therefore, in this stud
PMID 21212621

Japanese Journal

国分秀也,的場元弘,山田安彦,矢後和夫
YAKUGAKU ZASSHI 131(1), 113-127, 2011
… It was suggested that high serum concentrations of oxycodone and hydrocotarnine might be observed in geriatric patients or in the state of decreased hepatic blood flow, making dose adjustment is necessary for such patients. … We also clarified that the conversion ratio from oral oxycodone to intravenous ocycodone/hydrocotarnine was 0.71±0.12. …
NAID 130000451533

ITO Kiyomi,KUBOTA Yu,TODA Takahiro,SUTO Satoshi,IKARASHI Nobutomo,SUGIYAMA Kiyoshi
Drug metabolism and pharmacokinetics 24(1), 108-113, 2009-02-25
NAID 10025723071